Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality
- 1 August 2020
- journal article
- letter
- Published by Wolters Kluwer Health in Hypertension
- Vol. 76 (2) , E15-E17
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19Circulation Research, 2020
- Renin-Angiotensin System Blockers and the COVID-19 PandemicHypertension, 2020
- Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19New England Journal of Medicine, 2020
- Renoprotective Effect of Renin-Angiotensin-Aldosterone System Blockade in Patients With Predialysis Advanced Chronic Kidney Disease, Hypertension, and AnemiaJAMA Internal Medicine, 2014
- Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary DiseaseJACC, 2006